21.05.2015 MeVis Medical Solutions AG  DE000A0LBFE4

DGAP-News: MeVis Medical Solutions AG: MeVis Q1 2015: Mixed first quarter


 
DGAP-News: MeVis Medical Solutions AG / Key word(s): Quarter Results/Interim Report MeVis Medical Solutions AG: MeVis Q1 2015: Mixed first quarter 21.05.2015 / 10:19 --------------------------------------------------------------------- Very positive sales by strong US Dollar, declining results - Sales in the first quarter increased by 21 % to EUR 3.4 m due to the strong US dollar (previous year: EUR 2.8 m) - Earnings before interest and taxes (EBIT) decreased to EUR 0.5 m (previous year EUR 0.7 m), EBIT margin of 16 % - Net profit also declined slightly to EUR 0.7 m (previous year EUR 0.8 m) - Liquidity of EUR 19.0 m as at March 31, 2015 (Dec. 31, 2014: EUR 17.5 m) Bremen, May 21, 2015 - MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading provider of medical imaging software, today announced its results for the first quarter of 2015. Sales in the first quarter of 2015 came to EUR 3,408 k, 21 % higher than in the first quarter of 2014 (EUR 2,828 k). Revenues generated from licensing business increased by 17 % to TEUR 1,561, revenues from maintenance business increased by 9 % and accounted with TEUR 1,493 for 44 % of total sales. Sales in the Digital Mammography segment grew by 22 % to EUR 2,721 k (prev. year: EUR 2,227 k) and sales in the Other Diagnostics segment grew by 14 % to EUR 687 k (prev. year: EUR 601 k). Operating expenses increased slightly in the first quarter of 2014. Staff costs increased by only 1 % to EUR 1,837 k (prev. year: EUR 1,812 k). Other operating expenses rose by 34 % to EUR 549 k (prev. year: EUR 411 k) driven by legal and consulting cost. The capitalization of development expenses was ceased in the fourth quarter of 2014 (Q1 2014: EUR 428 k). Due to increased sales and despite higher costs and the cessation of the capitalization of development expenses, we see a slight increase of the EBITDA (earnings before interest, taxes, depreciation and amortization) by 1 %, from EUR 1,100 k to EUR 1,107 k. After depreciation and amortization of EUR 565 k (up 39 % year on year), EBIT (earnings before interest and taxes) declined considerably by 22 % to EUR 542 k (prev. year: EUR 694 k) corresponding to an EBIT margin of 16 % (prev. year: 25 %). The net financial result improved by EUR 59 k to EUR 138 k year on year. Mainly the development of the US$ exchange rate, the continuous improvement of the MeVis BreastCare, and the interest result have contributed to this. Income tax expenses decreased by EUR 46 k to EUR 42 k. Net profit fell by EUR 47 k to EUR 683 k, which is equivalent to earnings per share of EUR 0,37 (prev. year: 0,40). Cash and cash equivalents increased by EUR 1.453 k to EUR 18.964 k as of March 31, 2015 compared to the end of 2014. The Company's financial reports can be downloaded from the following website: http://www.mevis.de/en/investor-relations/financial-reports/ --------------------------------------------------------------------- 21.05.2015 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: MeVis Medical Solutions AG Caroline-Herschel-Str. 1 28359 Bremen Germany Phone: +49 421 224 95 0 Fax: +49 421 224 95 999 E-mail: [email protected] Internet: http://www.mevis.de ISIN: DE000A0LBFE4 WKN: A0LBFE Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart End of News DGAP News-Service --------------------------------------------------------------------- 360419 21.05.2015


Die wichtigsten Finanzdaten auf einen Blick
  2015 2016 2017 2018 2019 2020 2021e
Umsatzerlöse1 16,01 12,09 18,54 16,76 18,07 17,13 16,30
EBITDA1,2 6,41 5,25 9,18 7,60 8,25 5,97 5,30
EBITDA-Marge3 40,04 43,42 49,51 45,35 45,66 34,85 32,52
EBIT1,4 4,47 3,93 7,96 6,69 8,00 5,81 5,10
EBIT-Marge5 27,92 32,51 42,93 39,92 44,27 33,92 31,29
Jahresüberschuss1 6,74 3,43 5,62 7,17 8,07 5,70 4,40
Netto-Marge6 42,10 28,37 30,31 42,78 44,66 33,27 26,99
Cashflow1,7 6,58 3,51 7,32 5,52 6,55 2,89 3,40
Ergebnis je Aktie8 3,72 1,88 3,09 3,94 4,43 3,13 2,40
Dividende8 0,95 0,95 0,95 0,95 0,95 0,95 0,95
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2020 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: PricewaterhouseCoopers

INVESTOR-INFORMATIONEN
©boersengefluester.de
MeVis Med. Solutions
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A0LBFE 32,000 Halten 58,24
KGV 2022e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
13,91 10,25 1,36 12,14
KBV KCV KUV EV/EBITDA
3,27 20,15 3,40 9,45
Dividende '19 in € Dividende '20e in € Div.-Rendite '20e
in %
Hauptversammlung
0,95 0,95 2,97 24.03.2021
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
- 27.05.2021 - 28.01.2021
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-2,82% -2,04% 1,27% -1,84%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu MeVis Medical Solutions AG  ISIN: DE000A0LBFE4 können Sie bei DGAP abrufen

Medtech , A0LBFE , M3V , XETR:M3V